Hyderabad, March 28, 2019: Dr. Reddy’s Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY), along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Tadalafil Tablets USP, a therapeutic equivalent generic version of Cialis (tadalafil) Tablets in the United States market, approved by the U.S. Food and Drug Administration (USFDA).
The Cialis brand and generic had U.S. sales of approximately $1.7 billion MAT for the most recent twelve months ending in January 2019 according to IMS Health*.
Dr. Reddy’s Tadalafil Tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size.
Cialis is a trademark of Eli Lilly and Company.
*IMS National Sales Perspective: Retail and Non-Retail MAT January 2019
RDY-0319-242
Corporate Comm India(CCI Newswire)
